Metabolic Abnormalities in the Hippocampus of Patients with Schizophrenia: A 3D Multivoxel MR Spectroscopic Imaging Study at 3T

References

1. 1.↵
   2. Wu EQ,
   3. Birnbaum HG,
   4. Shi L, et al

   . The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122–29 doi:10.4088/JCP.v66n0906 pmid:16187769

   CrossRefPubMedWeb of Science
2. 2.↵
   American Psychiatric Association. American Psychiatric Association. DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013
3. 3.↵
   2. Malaspina D,
   3. Walsh-Messinger J,
   4. Gaebel W, et al

   . Negative symptoms, past and present: a historical perspective and moving to DSM-5. Eur Neuropsychopharmacol 2014;24:710–24 doi:10.1016/j.euroneuro.2013.10.018 pmid:24314851

   CrossRefPubMed
4. 4.↵
   2. Tamminga CA,
   3. Stan AD,
   4. Wagner AD

   . The hippocampal formation in schizophrenia. Am J Psychiatry 2010;167:1178–93 doi:10.1176/appi.ajp.2010.09081187 pmid:20810471

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Adriano F,
   3. Caltagirone C,
   4. Spalletta G

   . Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist 2012;18:180–200 doi:10.1177/1073858410395147 pmid:21531988

   Abstract/FREE Full Text
6. 6.↵
   2. Steen RG,
   3. Mull C,
   4. McClure R, et al

   . Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006;188:510–18 doi:10.1192/bjp.188.6.510 pmid:16738340

   Abstract/FREE Full Text
7. 7.↵
   2. Iritani S

   . Neuropathology of schizophrenia: a mini review. Neuropathology 2007;27:604–08 doi:10.1111/j.1440-1789.2007.00798.x pmid:18021384

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Samudra N,
   3. Ivleva EI,
   4. Hubbard NA, et al

   . Alterations in hippocampal connectivity across the psychosis dimension. Psychiatry Res 2015;233:148–57 doi:10.1016/j.pscychresns.2015.06.004 pmid:26123450

   CrossRefPubMed
9. 9.↵
   2. Kirov II,
   3. Hardy CJ,
   4. Matsuda K, et al

   . In vivo 7 Tesla imaging of the dentate granule cell layer in schizophrenia. Schizophr Res 2013;147:362–67 doi:10.1016/j.schres.2013.04.020 pmid:23664589

   CrossRefPubMed
10. 10.↵
    2. Wood SJ,
    3. Berger G,
    4. Velakoulis D, et al

    . Proton magnetic resonance spectroscopy in first episode psychosis and ultra-high-risk individuals. Schizophr Bull 2003;29:831–43 doi:10.1093/oxfordjournals.schbul.a007049 pmid:14989417

    Abstract/FREE Full Text
11. 11.↵
    2. Schobel SA,
    3. Lewandowski NM,
    4. Corcoran C, et al

    . Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 2009;66:938–46 doi:10.1001/archgenpsychiatry.2009.115 pmid:19736350

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Harrison PJ

    . The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 2004;174:151–62 pmid:15205886

    CrossRefPubMed
13. 13.↵
    2. Najjar S,
    3. Pearlman DM,
    4. Alper K, et al

    . Neuroinflammation and psychiatric illness. J Neuroinflammation 2013;10:43 doi:10.1186/1742-2094-10-43 pmid:23547920

    CrossRefPubMed
14. 14.↵
    2. Zhu H,
    3. Barker PB

    . MR spectroscopy and spectroscopic imaging of the brain. Methods Mol Biol 2011;711:203–26 doi:10.1007/978-1-61737-992-5_9 pmid:21279603

    CrossRefPubMed
15. 15.↵
    2. Lutkenhoff ES,
    3. van Erp TG,
    4. Thomas MA, et al

    . Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry 2010;15:308–18 doi:10.1038/mp.2008.87 pmid:18645571

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Schwerk A,
    3. Alves FD,
    4. Pouwels PJ, et al

    . Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies. J Neurochem 2014;128:1–87 doi:10.1111/jnc.12398 pmid:23937509

    CrossRefPubMed
17. 17.↵
    2. Nurnberger JI Jr.,
    3. Blehar MC,
    4. Kaufmann CA, et al

    . Diagnostic Interview for Genetic Studies: rationale, unique features, and training. Arch Gen Psychiatry 1994;51:849–59; discussion 863–64 doi:10.1001/archpsyc.1994.03950110009002 pmid:7944874

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Hetherington HP,
    3. Chu WJ,
    4. Gonen O, et al

    . Robust fully automated shimming of the human brain for high-field 1H spectroscopic imaging. Magn Reson Med 2006;56:26–33 doi:10.1002/mrm.20941 pmid:16767750

    CrossRefPubMed
19. 19.↵
    2. Goelman G,
    3. Liu S,
    4. Hess D, et al

    . Optimizing the efficiency of high-field multivoxel spectroscopic imaging by multiplexing in space and time. Magn Reson Med 2006;56:34–40 doi:10.1002/mrm.20942 pmid:16767711

    CrossRefPubMed
20. 20.↵
    2. Goelman G,
    3. Liu S,
    4. Fleysher R, et al

    . Chemical-shift artifact reduction in Hadamard-encoded MR spectroscopic imaging at high (3T and 7T) magnetic fields. Magn Reson Med 2007;58:167–73 doi:10.1002/mrm.21251 pmid:17659608

    CrossRefPubMed
21. 21.↵
    2. Mareci TH,
    3. Brooker HR

    . Essential considerations for spectral localization using indirect gradient encoding of spatial information. J Magn Reson 1991;92:229–46 doi:10.1016/0022-2364(91)90267-W

    CrossRef
22. 22.↵
    2. Brooker HR,
    3. Mareci TH,
    4. Mao JT

    . Selective Fourier transform localization. Magn Reson Med 1987;5:417–33 doi:10.1002/mrm.1910050503 pmid:3431402

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Goelman G,
    3. Liu S,
    4. Gonen O

    . Reducing voxel bleed in Hadamard-encoded MRI and MRS. Magn Reson Med 2006;55:1460–65 doi:10.1002/mrm.20903 pmid:16685718

    CrossRefPubMed
24. 24.↵
    2. de Graaf RA

    . In Vivo NMR Spectroscopy: Principles and Techniques. 2nd ed. Chichester, UK: John Wiley & Sons; 2007
25. 25.↵
    2. Barker PB,
    3. Bizzi A,
    4. Stefano ND, et al

    . Spectral analysis methods, quantitation and common artifacts. In: Clinical MR Spectroscopy Techniques and Applications. Cambridge: Cambridge University Press; 2010:34–50
26. 26.↵
    2. Brown TR,
    3. Kincaid BM,
    4. Ugurbil K

    . NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci U S A 1982;79:3523–26 doi:10.1073/pnas.79.11.3523 pmid:6954498

    Abstract/FREE Full Text
27. 27.↵
    2. Marion D,
    3. Ikura M,
    4. Bax A

    . Improved solvent suppression in one- and two-dimensional NMR spectra by convolution of time-domain data. J Magn Reson 1989;84:425–30 doi:10.1016/0022-2364(89)90391-0

    CrossRefWeb of Science
28. 28.↵
    2. Tal A,
    3. Gonen O

    . Localization errors in MR spectroscopic imaging due to the drift of the main magnetic field and their correction. Magn Reson Med 2013;70:895–904 doi:10.1002/mrm.24536 pmid:23165750

    CrossRefPubMed
29. 29.↵
    2. Soher BJ,
    3. Young K,
    4. Govindaraju V, et al

    . Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med 1998;40:822–31 doi:10.1002/mrm.1910400607 pmid:9840826

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Kirov I,
    3. George IC,
    4. Jayawickrama N, et al

    . Longitudinal inter- and intra-individual human brain metabolic quantification over 3 years with proton MR spectroscopy at 3 T. Mag Reson Med 2012;67:27–33 doi:10.1002/mrm.23001 pmid:21656555

    CrossRefPubMed
31. 31.↵
    2. Träber F,
    3. Block W,
    4. Lamerichs R, et al

    . 1H metabolite relaxation times at 3.0 Tesla: measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging 2004;19:537–45 doi:10.1002/jmri.20053 pmid:15112302

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Kirov I,
    3. Fleysher L,
    4. Fleysher R, et al

    . Age dependence of regional proton metabolites T2 relaxation times in the human brain at 3 T. Magn Reson Med 2008;60:790–95 doi:10.1002/mrm.21715 pmid:18816831

    CrossRefPubMed
33. 33.↵
    2. Posse S,
    3. Otazo R,
    4. Caprihan A, et al

    . Proton echo-planar spectroscopic imaging of J-coupled resonances in human brain at 3 and 4 Tesla. Mag Reson Med 2007;58:236–44 doi:10.1002/mrm.21287 pmid:17610279

    CrossRefPubMed
34. 34.↵
    2. Oishi K

    . MRI Atlas of Human White Matter. Amsterdam: Elsevier/Academic Press; 2011
35. 35.↵
    2. Ashburner J,
    3. Friston KJ

    . Unified segmentation. Neuroimage 2005;26:839–51 doi:10.1016/j.neuroimage.2005.02.018 pmid:15955494

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Tal A,
    3. Kirov I,
    4. Grossman RI, et al

    . The role of gray and white matter segmentation in quantitative proton MR spectroscopic imaging. NMR Biomed 2012;25:1392–400 doi:10.1002/nbm.2812 pmid:22714729

    CrossRefPubMedWeb of Science
37. 37.↵
    2. King KG,
    3. Glodzik L,
    4. Liu S, et al

    . Anteroposterior hippocampal metabolic heterogeneity: three-dimensional multivoxel proton 1H MR spectroscopic imaging–initial findings. Radiology 2008;249:242–50 doi:10.1148/radiol.2491071500 pmid:18695208

    CrossRefPubMed
38. 38.↵
    2. Vermathen P,
    3. Laxer KD,
    4. Matson GB, et al

    . Hippocampal structures: anteroposterior N-acetylaspartate differences in patients with epilepsy and control subjects as shown with proton MR spectroscopic imaging. Radiology 2000;214:403–10 doi:10.1148/radiology.214.2.r00fe43403 pmid:10671587

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Mazgaj R,
    3. Tal A,
    4. Goetz R, et al

    . Hypo-metabolism of the rostral anterior cingulate cortex associated with working memory impairment in 18 cases of schizophrenia. Brain Imaging Behav 2016;10:115–23 doi:10.1007/s11682-015-9372-x pmid:25804309

    CrossRefPubMed
40. 40.↵
    2. Heckers S,
    3. Konradi C

    . GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res 2015;167:4–11 doi:10.1016/j.schres.2014.09.041 pmid:25449711

    CrossRefPubMed
41. 41.↵
    2. Malaspina D,
    3. Storer S,
    4. Furman V, et al

    . SPECT study of visual fixation in schizophrenia and comparison subjects. Biol Psychiatry 1999;46:89–93 doi:10.1016/S0006-3223(98)00306-0 pmid:10394477

    CrossRefPubMedWeb of Science
42. 42.↵
    2. Lahti AC,
    3. Holcomb HH,
    4. Weiler MA, et al

    . Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry 2003;53:601–08 doi:10.1016/S0006-3223(02)01602-5 pmid:12679238

    CrossRefPubMedWeb of Science
43. 43.↵
    2. Tregellas JR,
    3. Smucny J,
    4. Harris JG, et al

    . Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia. Am J Psychiatry 2014;171:549–56 doi:10.1176/appi.ajp.2013.13070981 pmid:24435071

    CrossRefPubMed
44. 44.↵
    2. Poels EM,
    3. Kegeles LS,
    4. Kantrowitz JT, et al

    . Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res 2014;152:325–32 doi:10.1016/j.schres.2013.12.013 pmid:24418122

    CrossRefPubMed
45. 45.↵
    2. Sekar A,
    3. Bialas AR,
    4. de Rivera H, et al

    . Schizophrenia risk from complex variation of complement component 4. Nature 2016;530:177–83 doi:10.1038/nature16549 pmid:26814963

    CrossRefPubMed
46. 46.↵
    2. Hwang Y,
    3. Kim J,
    4. Shin JY, et al

    . Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl Psychiatry 2013;3:e321 doi:10.1038/tp.2013.94 pmid:24169640

    CrossRefPubMed
47. 47.↵
    2. van Erp TG,
    3. Hibar DP,
    4. Rasmussen JM, et al

    . Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry 2016;21:585 doi:10.1038/mp.2015.118 pmid:26283641

    CrossRefPubMed
48. 48.↵
    2. Bracken BK,
    3. Rouse ED,
    4. Renshaw PF, et al

    . T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia. Psychiatry Res 2013;213:142–53 doi:10.1016/j.pscychresns.2013.03.005 pmid:23769421

    CrossRefPubMed
49. 49.↵
    2. Sommer IE,
    3. van Westrhenen R,
    4. Begemann MJ, et al

    . Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014;40:181–91 doi:10.1093/schbul/sbt139 pmid:24106335

    Abstract/FREE Full Text